



3rd Long-Acting HIV Treatment and Prevention Conference

15 September 2026 | Johannesburg



From evidence to practice: What every clinician needs to know about long-acting agents

Moderator: Dr Catherine Martin, Wits RHI

Panel: Dr Mrinmayee Dhar, Bianca Kabasa, Lillian Melato, Wits RHI

Expert Panel



Dr Mrinmayee Dhar



Bianca Kabasa



Lillian Melato

Video demonstration: preparation of LEN





Video demonstration: injection technique



3rd LA ART Conference

LEN Leakage



Grading	2x2 gauze pad appearance	Cotton ball appearance
Mild: 2 x 2 inch gauze pad has a small volume of fluid absorbed		
Moderate: 2 x 2 inch gauze pad has a moderate volume of fluid absorbed; can still absorb more fluid		
Severe: 2 x 2 inch gauze pad is completely soaked through, beyond what it can absorb		

LEN Leakage may occur, and can be graded as Mild, Moderate or Severe

Figure: Visual representation and proposed leakage grading description based on PURPOSE and LEN treatment clinical trial guidance – Wits RHI TA Guidance Document (in draft)

Injection Site Reactions reported in PURPOSE 1 and PURPOSE 2



Table 7. Injection Site Reactions (All Grades) Reported in $\geq 2\%$ ^a of Participants Receiving YEZTUGO in PURPOSE 1 or PURPOSE 2

Injection Site Reactions	PURPOSE 1		PURPOSE 2	
	YEZTUGO N=2140	DESCOVY or TRUVADA ^b N=3205	YEZTUGO N=2183	TRUVADA ^b N=1088
Nodule	64%	17%	63%	39%
Pain	31%	24%	56%	53%
Induration	4%	<1%	16%	10%
Swelling	4%	5%	7%	10%
Pruritis	2%	1%	3%	3%
Erythema	1%	1%	17%	19%
Bruising	<1%	<1%	3%	4%
Warmth	<1%	<1%	2%	2%

- a. Frequencies are based on all injection site reactions attributed to study drug (or to the procedure) by the investigator.
- b. Participants received placebo subcutaneous injections (polyethylene glycol 400).

Source: US FDA Lenacapavir (YEZTUGO) injection/tablets label:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/220020s000lbl.pdf

Subcutaneous administration of LEN





Image: Claude AI

3rd LA ART Conference

Available Tools and Resources



To access lenacapavir preparation and administration videos, scan this QR code or go to myprep.co.za



Adverse Drug Reactions should be reported to SAHPRA, WHO or equivalent regulatory authority

For more details on SAHPRA ADR reporting

